000			04411nam a2200397 i 4500
999			_c393070 _d393070 _x1
001			393070
003			ES-MaUEC
005			20240314174315.0
006			a|||| o|||| 00| 0
007			cr nn 008mamaa
008			100301s2000 xxu| o |||| 0|eng d
020			_a9781592590797
024	7		_a10.1385/1592590799 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC280 .L5 _b200 EB
245	0	0	_aHepatocellular Carcinoma : _bMethods and Protocols _cedited by Nagy A. Habib
250			_a1st edition 2000
264		1	_aTotowa, NJ _bHumana Press _c2000
300			_a1 recurso en línea (XIII, 302 páginas)
336			_atexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_aarchivo de texto _bPDF
490	0		_aMethods in Molecular Medicine _x1940-6037 _v45
505	0		_aThe Clinical Problem -- Hepatocellular Carcinoma -- Medical Management of Hepatocellular Carcinoma -- HCC Carcinogenesis -- Possible Involvement of the NS3 Protein of Hepatitis C Virus in Hepatocarcinogenesis -- Abrogation of p53-Induced Apoptosis by the Hepatitis B Virus X Gene -- Hepatocellular Carcinoma -- Molecular and Biological Characteristics -- The Impact of Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) -- Mutation of p53 Tumor Suppressor Gene in Hepatocellular Carcinoma -- Diagnostic Markers in Hepatocellular Carcinoma Using Immunohistochemical Techniques -- Assessing Matrix Metalloproteinase Expression and Activity in Hepatocellular Carcinomas -- Isolation of Novel Markers for Hepatocellular Carcinoma by a Subtraction-Enhanced Display Technique -- Measurement of Protein Expression of p53, p21WAF1, and Rb in Patients with Surgically Treated Hepatocellular Carcinoma by Using Catalyzed Signal-Amplification System -- HCC Gene Therapy -- Gene Therapy Vectors Harboring AFP Regulatory Sequences -- Advantages and Disadvantages of Multiple Different Methods of Adenoviral Vector Construction -- Electron Microscopic Assessment of Adenovirus-Mediated Transfer -- p53 Plasmid Preparation and Techniques for Analysis of Gene Transfer and Expression -- Antisense IGF-I for Hepatocellular Carcinoma -- Novel Effective Tumor Vaccines for Hepatocellular Carcinoma -- Immunoglobulin Fusion Proteins as a Tool for Evaluation of T-Cell Costimulatory Molecules -- Adenovirus-Mediated Drug-Sensitivity Gene Therapy for Hepatocellular Carcinoma -- Clinical Protocol for P53 Gene Therapy for Liver Tumors -- Clinical Protocol for p53 Gene Therapy for Liver Tumors.
520			_aAdvances in molecular characterization and novel gene-isolation techniques have vigorously expanded our understanding of hepatocellular carcinoma (HCC), a form of liver cancer that affects one million people annually, and generated many new therapeutic possibilities. In Hepatocellular Carcinoma: Methods and Protocols, Nagy Habib and a team of basic and clinical researchers describe the wide variety of powerful new laboratory-based molecular methods currently being used for investigating and treating this disease. The book focuses on gene therapy approaches, including the use of such vectors as lipids, adenovirus, and baculovirus, and virus detection assessment using electron microscopy. It also provides preclinical and clinical data on the killing of cancer cells using tumor-suppressor genes, antisense compounds to growth factors, immunotherapy (remove gene), and virus-directed enzyme prodrug therapy. A perspective on future treatment of the failing liver is given, along with a clinical protocol for p53 gene therapy. Hepatocellular Carcinoma: Methods and Protocols offers experimental and clinical investigators a rich source of both basic science and clinical information on today's optimal use of gene therapy to treat and manage patients suffering from hepatocellular carcinoma.
988			_aSpringer_Protocols_2000
650		7	_2embne _9413204 _aHígado _xCáncer _vManuales de laboratorio
776	0	8	_iPrinted edition: _z9781489941695
776	0	8	_iPrinted edition: _z9780896037854
776	0	8	_iPrinted edition: _z9781489941688
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1385/1592590799 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b01/2024 _dz _eb _zSI